A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies

NCT02205333 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

48

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated early at the sponsor's discretion.

Conditions

Advanced Solid Tumors
Aggressive B-cell Lymphomas

Interventions

BIOLOGICAL: MEDI6469 Monotherapy
BIOLOGICAL: MEDI6469 Plus Tremelimumab
BIOLOGICAL: MEDI6469 Plus Durvalumab
BIOLOGICAL: MEDI6469 plus Rituximab

Sponsor

MedImmune LLC